A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids
MP Diamond, EA Stewart, ARW Williams… - Human …, 2019 - academic.oup.com
STUDY QUESTION What is the safety and efficacy profile during long-term (12–24 months)
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
[HTML][HTML] A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids
MP Diamond, EA Stewart, ARW Williams… - Human Reproduction …, 2019 - ncbi.nlm.nih.gov
STUDY DESIGN, SIZE, DURATION: Women with uterine fibroids who had previously
received placebo (n= 87) or asoprisnil 10 mg (n= 221) or 25 mg (n= 215) for 12 months in …
received placebo (n= 87) or asoprisnil 10 mg (n= 221) or 25 mg (n= 215) for 12 months in …
A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
MP Diamond, EA Stewart, ARW Williams… - Human Reproduction …, 2019 - europepmc.org
STUDY DESIGN, SIZE, DURATION: Women with uterine fibroids who had previously
received placebo (n= 87) or asoprisnil 10 mg (n= 221) or 25 mg (n= 215) for 12 months in …
received placebo (n= 87) or asoprisnil 10 mg (n= 221) or 25 mg (n= 215) for 12 months in …
A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
MP Diamond, EA Stewart, ARW Williams… - Human Reproduction …, 2019 - go.gale.com
STUDY QUESTION: What is the safety and efficacy profile during long-term (12-24 months)
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
[PDF][PDF] A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids
MP Diamond, EA Stewart, ARW Williams, BR Carr… - 2019 - pdfs.semanticscholar.org
STUDY DESIGN, SIZE, DURATION: Women with uterine fibroids who had previously
received placebo (n= 87) or asoprisnil 10 mg (n= 221) or 25 mg (n= 215) for 12 months in …
received placebo (n= 87) or asoprisnil 10 mg (n= 221) or 25 mg (n= 215) for 12 months in …
A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids
MP Diamond, EA Stewart… - Human …, 2019 - pubmed.ncbi.nlm.nih.gov
Study question What is the safety and efficacy profile during long-term (12-24 months)
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
[PDF][PDF] A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids
MP Diamond, EA Stewart, ARW Williams… - Human …, 2019 - academic.oup.com
STUDY QUESTION What is the safety and efficacy profile during long-term (12–24 months)
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
MP Diamond, EA Stewart… - Human …, 2019 - search.ebscohost.com
STUDY QUESTION What is the safety and efficacy profile during long-term (12–24 months)
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …
uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 …